Author:
Hasselgren Catrin,Myatt Glenn J.
Reference43 articles.
1. DiMasi JA, Grabowski HG, Hansen RW (2016) Innovation in the pharmaceutical industry: new estimates of R&D costs. J Health Econ 47:20–33
2. Kola I, Landis J (2004) Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 3:711–716
3. Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G, Pangalos MN (2014) Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework. Nat Rev Drug Discov 13:419–431
4. Harpaz R, Callahan A, Tamang S, Low Y, Odgers D, Finlayson S, Jung K, LePendu P, Shah NH (2014) Text mining for adverse drug events: the promise, challenges, and state of the art. Drug Saf 37:777–790
5. Administration FaD FDA Adverse Event Reporting System (FAERS) (2017).
https://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Surveillance/AdverseDrugEffects/default.htm
Cited by
14 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Artificial Intelligence for Drug Discovery: Are We There Yet?;Annual Review of Pharmacology and Toxicology;2024-01-23
2. Computational Toxicological Approaches for Drug Profiling and Development of Online Clinical Repositories;Computational Toxicology for Drug Safety and a Sustainable Environment;2023-12-17
3. Applications of Computational Toxicology in Pharmaceuticals, Environmental and Industrial Practices;Computational Toxicology for Drug Safety and a Sustainable Environment;2023-12-17
4. Microrna-96 In Human Cancers;Combinatorial Chemistry & High Throughput Screening;2023-06
5. The Use of Machine Learning to Support Drug Safety Prediction;Machine Learning and Deep Learning in Computational Toxicology;2023